Recruiting
Phase 3

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Sponsor:

ECOG-ACRIN Cancer Research Group

Code:

NCT02201992

Conditions

ALK Gene Rearrangement

ALK Gene Translocation

ALK Positive

Stage IB Non-Small Cell Lung Carcinoma AJCC v7

Stage II Non-Small Cell Lung Cancer AJCC v7

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Clinical Observation

Crizotinib

Laboratory Biomarker Analysis

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information